

**Supplementary Table 1.**

<b>Variable</b>		<b>Odds Ratio (OR)</b>	<b>95%CI</b>
<i>Age at metastasis diagnosis (per 1 year increase)</i>		0.96	0.92-0.99
<i>Metastasis location: Lungs</i>		0.72	0.07-7.02
<i>Metastasis location: Soft tissue and/or lymph nodes</i>		2.47	0.12-49.34
<i>Primary surgery: Amputation</i>		0.50	0.04-6.05
<i>ECOG performance status (per 1 point increase)</i>		0.83	0.29-2.35
<i>Tumour grade G3</i>		2.97	0.57-15.58
<i>Location of primary tumour: Upper</i>		0.31	0.03-3.74
<i>Location of primary tumour: Lower</i>		0.26	0.02-2.85
<i>Histology: MPNST</i>		0.93	0.04-23.01
<i>Histology: Myxofibrosarcoma</i>		2.16	0.37-12.68
<i>Histology: Synovial Sarcoma</i>		0.80	0.04-16.70
<i>Histology: Others</i>		0.73	0.10-5.29
<i>Female Gender</i>		1.86	0.48-7.23
<i>Time to metachronous metastasis (per 1 month increase)</i>		0.98	0.95-1.02
<i>Multiple metastases</i>		0.86	0.18-4.05
<i>Metastasis count (per 1 metastasis increase)*</i>		0.67	0.52-0.85
<i>Study centre: #2</i>		0.48	0.06-4.13
<i>Haemoglobin (per 1 g/dL increase)</i>		0.93	0.57-1.52
<i>Albumin (per 1 g/L increase)</i>		6.44	1.37-30.16
<i>(Neo-)Adjuvant radiotherapy</i>		3.63	0.04-370.11

<i>No adjuvant therapy (neither chemo nor radiation)</i>		1.30	0.03-51.64
--	--	------	------------

**Supplementary Table 2.**

<b>Treatment</b>		<b>n=135</b>	<b>%</b>
<i>Conservative / Best-Supportive-Care (BSC) only</i>		32	23.7
<i>RTX</i>		7	5.2
<i>CTX</i>		24	17.8
<i>CTX + RTX</i>		4	3.0
<i>Surgery</i>		32	23.7
<i>Surgery + RTX</i>		10	7.4
<i>Surgery + CTX</i>		25	18.5
<i>Surgery + RTX + CTX</i>		1	0.7